(ICTV) ICoToV. EC 51, Berlin, Germany, July 2019; Email ratification March 2020 (MSL #35). 2019.
Damon IK. Poxviruses. 6th ed. In: Knipe DM, Howley PM, editors. Fields Virology, vol. 2. Lippincott; 2013. p. 2160–84.
Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology, vol. 2. Lippincott; 2013. p. 2129–59.
Google Scholar
Esposito JJ, Sammons SA, Frace AM, Osborne JD, Olsen-Rasmussen M, Zhang M, et al. Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science. 2006;313(5788):807–12.
Article
PubMed
Google Scholar
Hopkins, DR. (1980). Ramses V: earliest know victim?. World Health, p.22–6. https://apps.who.int/iris/handle/10665/202495
Fenner FHD, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
Google Scholar
Crosby AW (1993). Smallpox. In K.F. Kiple, (pp 1008–14). Cambridge: Cambridge University Press.
Henderson DA. The eradication of smallpox–an overview of the past, present, and future. Vaccine. 2011;29(Suppl 4):D7-9.
Article
PubMed
Google Scholar
Edwardes EJ. A concise history of small-pox and vaccination in Europe. London: H.K. Lewis; 1902.
Google Scholar
Chang CF. Disease and its impact on politics, diplomacy, and the military: the case of smallpox and the Manchus (1613–1795). J Hist Med Allied Sci. 2002;57(2):177–97.
Article
PubMed
Google Scholar
Fenner F. The global eradication of smallpox. Med J Aust. 1980;1(10):455–65.
Article
CAS
PubMed
Google Scholar
Noyce RS, Lederman S, Evans DH. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE. 2018;13(1):e0188453.
Article
PubMed
PubMed Central
CAS
Google Scholar
McCarthy M. Smallpox samples are found in FDA storage room in Maryland. BMJ. 2014;349:g4545.
Article
PubMed
Google Scholar
Institute of Medicine (US) Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. Protecting our forces: improving vaccine acquisition and availability in the U.S. military. Lemon SM, Thaul S, Fisseha S, Maonaigh HC, editors. Washington, DC: The National Academies Press; 2002. 158p.
Hoy SM. Tecovirimat: first global approval. Drugs. 2018;78(13):1377–82.
Article
CAS
PubMed
Google Scholar
Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, et al. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir Ther. 2008;13(8):977–90.
CAS
PubMed
Google Scholar
Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003;57(1–2):41–52.
Article
CAS
PubMed
Google Scholar
Jesus DM, Costa LT, Goncalves DL, Achete CA, Attias M, Moussatche N, et al. Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol. 2009;83(22):11477–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Andrei G, Snoeck R. Cidofovir activity against poxvirus infections. Viruses. 2010;2(12):2803–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Robbins SJ, Jackson RJ, Fenner F, Beaton S, Medveczky J, Ramshaw IA, et al. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. Antiviral Res. 2005;66(1):1–7.
Article
CAS
PubMed
Google Scholar
Editorial. The spectre of smallpox lingers. Nature 2018;560(7718):281.
Institution of Medicine. Live Variola Virus: Consideration for Continuing Research (2009). 2009.
Reynolds MG, Holman RC, Yorita Christensen KL, Cheek JE, Damon IK. The incidence of molluscum contagiosum among American Indians and Alaska Natives. PLoS ONE. 2009;4(4):e5255.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mendez-Rios JD, Martens CA, Bruno DP, Porcella SF, Zheng ZM, Moss B. Genome sequence of erythromelalgia-related poxvirus identifies it as an ectromelia virus strain. PLoS ONE. 2012;7(4):e34604.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zheng ZM, Specter S, Zhang JH, Friedman H, Zhu WP. Further characterization of the biological and pathogenic properties of erythromelalgia-related poxviruses. J Gen Virol. 1992;73(Pt 8):2011–19.
Article
PubMed
Google Scholar
Zheng ZM, Zhang JH, Hu JM, Liu SF, Zhu WP. Poxviruses isolated from epidemic erythromelalgia in China. Lancet. 1988;1(8580):296.
Article
CAS
PubMed
Google Scholar
Department of Health and Social Services. Second case of Novel orthopoxvirus infection in a Fairbanks-area resident. State of Alaska Epidemiology Bulletin. 2020(11).
Springer YP, Hsu CH, Werle ZR, Olson LE, Cooper MP, Castrodale LJ, et al. Novel orthopoxvirus infection in an Alaska resident. Clin Infect Dis. 2017;64(12):1737–41.
Article
PubMed
PubMed Central
Google Scholar
Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA. 2010;107(37):16262–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al. Emergence of Monkeypox—West and Central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep. 2018;67(10):306–10.
Article
PubMed
PubMed Central
Google Scholar
Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018;23(38):1800509.
Article
PubMed Central
Google Scholar
Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, et al. Diagnosis of imported Monkeypox, Israel, 2018. Emerg Infect Dis. 2019;25(5):980–3.
Article
PubMed
PubMed Central
Google Scholar
Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu K, Vasoo S, et al. Imported Monkeypox, Singapore. Emerg Infect Dis. 2020;26(8):1826–30.
Article
PubMed
PubMed Central
Google Scholar
Ng OT, Lee V, Marimuthu K, Vasoo S, Chan G, Lin RTP, et al. A case of imported Monkeypox in Singapore. Lancet Infect Dis. 2019;19(11):1166.
Article
PubMed
PubMed Central
Google Scholar
Centers for Disease C, Prevention. Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003;52(27):642–6.
Tuppurainen ESM, Venter EH, Shisler JL, Gari G, Mekonnen GA, Juleff N, et al. Review: capripoxvirus diseases: current status and opportunities for control. Transbound Emerg Dis. 2017;64(3):729–45.
Article
CAS
PubMed
Google Scholar
Weli SC, Tryland M. Avipoxviruses: infection biology and their use as vaccine vectors. Virol J. 2011;8:49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pello SJ, Olsen GH. Emerging and reemerging diseases of avian wildlife. Vet Clin North Am Exot Anim Pract. 2013;16(2):357–81.
Article
PubMed
Google Scholar
History – Edward Jenner (1749–1823). BBC. 1 November 2006. https://www.bbc.co.uk/history/historic_figures/jenner_edward.shtml
Steinhardt E, Israeli C, Lambert RA. Studies on the cultivation of the virus of vaccinia†. J Infect Dis. 1913;13(2):294–300.
Article
Google Scholar
Moss B. 5’ end labeling of RNA with capping and methylating enzymes. Gene Amplif Anal. 1981;2:253–66.
CAS
PubMed
Google Scholar
Wei C, Moss B. 5’-Terminal capping of RNA by guanylyltransferase from HeLa cell nuclei. Proc Natl Acad Sci USA. 1977;74(9):3758–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munyon W, Paoletti E, Grace JT Jr. RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci USA. 1967;58(6):2280–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kates JR, McAuslan BR. Poxvirus DNA-dependent RNA polymerase. Proc Natl Acad Sci USA. 1967;58(1):134–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shuman S. Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli. J Biol Chem. 1990;265(20):11960–6.
Article
CAS
PubMed
Google Scholar
Geng L, Xin W, Huang DW, Feng G. A universal cloning vector using vaccinia topoisomerase I. Mol Biotechnol. 2006;33(1):23–8.
CAS
PubMed
Google Scholar
Moss B. Poxvirus cell entry: how many proteins does it take? Viruses. 2012;4(5):688–707.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, Ferguson BJ, et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol. 2013;94(Pt 11):2367–92.
Article
CAS
PubMed
Google Scholar
Meade N, King M, Munger J, Walsh D. mTOR dysregulation by vaccinia virus F17 controls multiple processes with varying roles in infection. J Virol. 2019. https://doi.org/10.1128/JVI.00784-19.
Article
PubMed
PubMed Central
Google Scholar
Eaglesham JB, Pan Y, Kupper TS, Kranzusch PJ. Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling. Nature. 2019;566(7743):259–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pant A, Dsouza L, Cao S, Peng C, Yang Z. Viral growth factor- and STAT3 signaling-dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection. PLoS Pathog. 2021;17(2):e1009303.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pant A, Yang Z. Asparagine: an achilles heel of virus replication? ACS Infect Dis. 2020;6(9):2301–3.
Article
CAS
PubMed
Google Scholar
Dhungel P, Cantu FM, Molina JA, Yang Z. Vaccinia virus as a master of host shutoff induction: targeting processes of the central dogma and beyond. Pathogens. 2020;9(5):400.
Article
CAS
PubMed Central
Google Scholar
Pant A, Cao S, Yang Z. Asparagine is a critical limiting metabolite for vaccinia virus protein synthesis during glutamine deprivation. J Virol. 2019. https://doi.org/10.1128/JVI.01834-18.
Article
PubMed
PubMed Central
Google Scholar
Dhungel P, Cao S, Yang Z. The 5’-poly(A) leader of poxvirus mRNA confers a translational advantage that can be achieved in cells with impaired cap-dependent translation. PLoS Pathog. 2017;13(8):e1006602.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dai A, Cao S, Dhungel P, Luan Y, Liu Y, Xie Z, et al. Ribosome profiling reveals translational upregulation of cellular oxidative phosphorylation mrnas during vaccinia virus-induced host shutoff. J Virol. 2017. https://doi.org/10.1128/JVI.01858-16.
Article
PubMed
PubMed Central
Google Scholar
Cantu F, Cao S, Hernandez C, Dhungel P, Spradlin J, Yang Z. Poxvirus-encoded decapping enzymes promote selective translation of viral mRNAs. PLoS Pathog. 2020;16(10):e1008926.
Article
CAS
PubMed
PubMed Central
Google Scholar
Perkus ME, Piccini A, Lipinskas BR, Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985;229(4717):981–4.
Article
CAS
PubMed
Google Scholar
Paoletti E, Perkus ME, Piccini A. Live recombinant vaccines using genetically engineered vaccinia virus. Antivir Res. 1985;5(Suppl1):301–7.
Article
Google Scholar
Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983;25(1):21–8.
Article
CAS
PubMed
Google Scholar
Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci USA. 2010;107(25):11513–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang Z, Reynolds SE, Martens CA, Bruno DP, Porcella SF, Moss B. Expression profiling of the intermediate and late stages of poxvirus replication. J Virol. 2011;85(19):9899–908.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang Z, Maruri-Avidal L, Sisler J, Stuart CA, Moss B. Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters. Virology. 2013;447(1–2):213–20.
Article
CAS
PubMed
Google Scholar
Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 1984;311(5986):578–9.
Article
CAS
PubMed
Google Scholar
Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol. 2017;2(11):eaa111713.
Article
Google Scholar
Moss B, Smith GL, Mackett M. Use of vaccinia virus as an infectious molecular cloning and expression vector. Gene Amplif Anal. 1983;3:201–13.
CAS
PubMed
Google Scholar
Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA. 1982;79(23):7415–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA. 1984;81(1):193–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Panicali D, Davis SW, Weinberg RL, Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA. 1983;80(17):5364–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA. 1982;79(16):4927–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smith GL, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983;302(5908):490–5.
Article
CAS
PubMed
Google Scholar
Moss B. Reflections on the early development of poxvirus vectors. Vaccine. 2013;31(39):4220–2.
Article
PubMed
PubMed Central
Google Scholar
Brochier B, Costy F, Pastoret PP. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet Microbiol. 1995;46(13):269–79.
Article
CAS
PubMed
Google Scholar
Wiktor TJ, MacFarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene 1984. Biotechnology. 1992;24:508–12.
CAS
PubMed
Google Scholar
Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984;312(5990):163–6.
Article
CAS
PubMed
Google Scholar
Brochier B, Kieny MP, Costy F, Coppens P, Bauduin B, Lecocq JP, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991;354(6354):520–2.
Article
CAS
PubMed
Google Scholar
Slate D, Rupprecht CE, Rooney JA, Donovan D, Lein DH, Chipman RB. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res. 2005;111(1):68–76.
Article
CAS
PubMed
Google Scholar
Rupprecht CE, Wiktor TJ, Johnston DH, Hamir AN, Dietzschold B, Wunner WH, et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA. 1986;83(20):7947–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA. 1984;81(22):7194–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13(6):539–49.
Article
CAS
PubMed
Google Scholar
Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Vet Res. 2004;35(4):425–43.
Article
CAS
PubMed
Google Scholar
Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, et al. Development and use of fowlpox vectored vaccines for avian influenza. Ann N Y Acad Sci. 2006;1081:193–201.
Article
PubMed
Google Scholar
Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, Garcia-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses. 2015;7(4):1726–803.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park Y, et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun. 2020;11(1):6121.
Article
CAS
PubMed
PubMed Central
Google Scholar
Garcia-Arriaza J, Garaigorta U, Perez P, Lazaro-Frias A, Zamora C, Gastaminza P, et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J Virol. 2021. https://doi.org/10.1128/JVI.02260-20.
Article
PubMed
PubMed Central
Google Scholar
Liu R, Americo JL, Cotter CA, Earl PL, Erez N, Peng C, et al. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proc Natl Acad Sci USA. 2021;118(12):e2026785118.
Article
PubMed
CAS
PubMed Central
Google Scholar
Routhu NK, Cheedarla N, Gangadhara S, Bollimpelli VS, Boddapati AK, Shiferaw A, et al. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity. 2021;54(3):542-56 e9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Donnelly O, Harrington K, Melcher A, Pandha H. Live viruses to treat cancer. J R Soc Med. 2013;106(8):310–4.
Article
PubMed
PubMed Central
Google Scholar
Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5(1):e1115641.
Article
PubMed
CAS
Google Scholar
Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, et al. Antitumor effect of vaccinia virus in glioma model. Oncol Res. 1999;11(3):133–44.
CAS
PubMed
Google Scholar
Evgin L, Vaha-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, et al. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther. 2010;18(5):896–902.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, et al. Cowpox virus: a new and armed oncolytic poxvirus. Mol Ther Oncolytics. 2017;7:1–11.
Article
PubMed
PubMed Central
Google Scholar
Rahman MM, McFadden G. Oncolytic virotherapy with myxoma virus. J Clin Med. 2020;9(1):171.
Article
CAS
PubMed Central
Google Scholar
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hu Y, Lee J, McCart JA, Xu H, Moss B, Alexander HR, et al. Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol. 2001;75(21):10300–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99–102.
Article
CAS
PubMed
Google Scholar
Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008;16(9):1637–42.
Article
CAS
PubMed
Google Scholar
Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006;14(3):361–70.
Article
CAS
PubMed
Google Scholar
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20(4):749–58.
Article
CAS
PubMed
Google Scholar
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer. Mol Ther. 2015;23(9):1532–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015;23(3):602–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH. A Phase 2, Open-label, randomized study of Pexa-Vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma. Methods Mol Biol. 2015;1317:343–57.
Article
PubMed
Google Scholar
Sarker S, Athukorala A, Bowden TR, Boyle DB. Genomic characterisation of a novel avipoxvirus isolated from an endangered yellow-eyed penguin (Megadyptes antipodes). Viruses. 2021;13(2):194.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stanford MM, McFadden G. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther. 2007;7(9):1415–25.
Article
CAS
PubMed
Google Scholar